Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.
/ 1653 items
#XY↓
Alnylam Teams Up with ChatGPT Creator’s AI Company to Revolutionize RNAi Therapeutics
Alnylam Pharmaceuticals partners with AI startup Inceptive in a deal worth up to $2 billion to accelerate discovery of next-generation RNAi therapeutics using powerful AI models.
Lilly and Ascidian Sign $1.9B Deal to Bring RNA Gene Editing to Genetic Kidney Diseases
Eli Lilly teams with Ascidian to use RNA editing to treat rare kidney diseases without changing DNA.
Wells Fargo Boosts Oscar Health Rating as Exchange Outlook Improves
Wells Fargo upgraded Oscar Health, citing a better 2026 outlook, improving costs, and stronger-than-expected enrollment.
UnitedHealth Stock Gets a Bullish Boost: BofA Sees Strong Risk/Reward Ahead
Bank of America upgraded UNH to Buy, raising target to $450 as lower healthcare costs boost earnings outlook.
ADC Therapeutics Stock Falls as Safety Worries Overshadow Strong ZYNLONTA Trial Results
ADC Therapeutics fell by nearly half after ZYNLONTA showed better cancer control but higher rates of serious side effects and deaths.